Search Results
Your search for ,had matches 18604 pages
Showing 11901 - 11950Rucaparib Leads to Frequent Durable Remissions in BRCA-Mutated Relapsed Ovarian Cancer
Rucaparib (Rubraca) led to frequent durable remissions among patients with relapsed high-grade ovarian cancer with BRCA mutations, regardless of whether the mutations were germline or somatic, according to the results of the ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual...
ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...
Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options
A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...
An Oncology Care Model: One Institute’s Experience
At this year’s ASCO Quality Care Symposium, Blase N. Polite, MD, MPP, Associate Professor of Medicine at The University of Chicago Medical Center, examined his practice’s experience with the Oncology Care Model, a Centers for Medicare & Medicaid Services test payment and delivery program...
Machine Learning Model Predicts Colorectal Cancer Recurrence
A machine learning model that uses a set or ensemble of algorithms has good accuracy for predicting colorectal cancer recurrence, investigators reported during a plenary session at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 Persistent key questions in managing early...
FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers
On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was previously approved for people...
Expert Point of View: Suzanne L. Topalian, MD
“Avelumab (Bavencio) is the very first drug approved for Merkel cell carcinoma, an orphan disease that is uncommon in the United States. For that reason, pharmacologic development has been slow. In this case, laboratory evidence provided a rationale for testing checkpoint inhibitors in Merkel cell ...
Avelumab Produces Durable Responses in Merkel Cell Carcinoma, Becomes First Drug Approved for the Rare Disease
Avelumab (Bavencio) achieved durable responses in patients with metastatic Merkel cell carcinoma, according to longer-term follow-up of the phase II JAVELIN study, the largest study conducted to date in this relatively rare orphan cancer.1 Results were presented at the 2017 American Association for ...
Deintensifiying Treatment of HPV-Positive Oropharyngeal Cancer Could Reduce Toxicity While Maintaining Function and Survival
“The status quo for HPV [human papillomavirus]-associated oropharyngeal squamous cell carcinoma is not sufficient.… Our treatment is effective, but the toxicity associated with it is not tolerable.” And HPV-associated oropharyngeal cancer “is a cancer of relatively younger patients,” said Nishant...
Resilience Linked to Less Distress in Lesbian and Bisexual Breast Cancer Survivors
Breast cancer can have a pervasive effect on a woman’s psychological functioning, but sexual minority (ie, lesbian and bisexual) breast cancer survivors are underrepresented in studies of psychological distress, according to Charles Kamen, PhD, a clinical psychologist at the University of Rochester ...
Next-Generation Genitourinary Oncology: Keeping One’s Powder Dry
There is a new yin-yang of management in genitourinary oncology, with the balance of opposing power focused among cancer cells, kinase inhibition, and lymphocyte function, representing a shift in the fashions of treatment somewhat away from chemotherapy. This linear progress has been complicated...
Expert Point of View: Rodrigo Dienstmann, MD
“This is one of the most beautiful stories we have in translational precision oncology research in colorectal cancer. We have robust preclinical data, rigorous molecular diagnosis, and successful clinical results,” said formal discussant of this trial, Rodrigo Dienstmann, MD, of Vall D’Hebron...
Conditional Survival After Initial Diagnosis and Treatment of Stage III Melanoma
In an Australian study reported in the Journal of Clinical Oncology, Haydu et al found that conditional melanoma-specific survival was worse within the first 2 years of diagnosis of stage III disease for men, increasing age, and increasing American Joint Committee on Cancer (AJCC) stage. The...
Effect of Radiotherapy Boost for Ductal Carcinoma in Situ After Whole-Breast Radiotherapy
In an analysis reported in JAMA Oncology, Moran et al found that a radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy was associated with a reduction in the risk for ipsilateral breast tumor recurrence. Study Details The analysis pooled...
Dual HER2 Targeting of HER2-Positive Metastatic Colorectal Cancer Shows Clinical Benefit
The combination of trastuzumab (Herceptin) plus lapatinib (Tykerb) achieved positive results in patients with heavily pretreated, HER2-positive metastatic colorectal cancer, according to the final results of the phase II HERACLES-A trial. This two-pronged, HER2-directed approach achieved clinical...
FDA Removes Risk Evaluation and Mitigation Strategy Requirements for Erythropoiesis-Stimulating Agents
On April 13, the U.S. Food and Drug Administration (FDA) removed the risk evaluation and mitigation strategy (REMS) requirements for the use of epoetin alfa and darbepoetin alfa to treat patients with anemia due to associated myelosuppressive chemotherapy. The Agency's announcement regarding...
Satisfaction With Surgical Decision-Making in Women Considering Contralateral Prophylactic Mastectomy for Breast Cancer
In a study reported in JAMA Surgery, Katz et al found that most patients considering contralateral prophylactic mastectomy for stage 0 to II breast cancer were satisfied with surgical decision-making. Most surgeons discussed contralateral prophylactic mastectomy and most did not recommend against...
Predicting Metastatic Disease After Radical Prostatectomy
An individual patient-level meta-analysis has shown that the Decipher® (GenomeDx) genomic classifier is capable of distinguishing risk groups for metastatic disease after radical prostatectomy for prostate cancer. The study was reported by Spratt and colleagues in the Journal of Clinical...
Study Finds Vaccine-Chemotherapy Combination Prolongs Overall Survival in Glioblastoma
Despite highly aggressive therapy that includes maximal tumor resection, high-dose radiation, and temozolomide chemotherapy, the prognosis for patients with newly diagnosed glioblastoma is dismal, with a median survival of less than 15 months, prompting researchers to study novel approaches to...
Ratio of T-Cell Invigoration to Tumor Burden Associated With Immunotherapeutic Response
Matching the size of a tumor to the body’s immune response could help physicians tailor immunotherapy treatments for patients with metastatic melanoma. Researchers found that patients who didn’t respond to treatment had an imbalance between the size of their tumor and how exhausted...
Cigarette Smoking and Survival in Pancreatic Cancer
A study of data from large prospective U.S. cohorts has shown that current cigarette smoking, greater pack-years, and heavy smoking were associated with poorer survival among patients with pancreatic cancer. The study was reported by Yuan et al in the Journal of Clinical Oncology. Study Details...
Spanish Trial Shows Benefit of Vinflunine Maintenance in Advanced Urothelial Carcinoma
In a Spanish phase II trial reported in The Lancet Oncology, García-Donas et al found that maintenance therapy with vinflunine improved progression-free survival vs best supportive care alone in patients with advanced urothelial carcinoma with disease control on first-line chemotherapy....
Blinatumomab After Failure of TKI Treatment in B-Precursor Acute Lymphoblastic Leukemia
In a phase II trial reported in the Journal of Clinical Oncology, Martinelli et al found that blinatumomab (Blincyto) produced complete responses in patients with relapsed/refractory Philadelphia chromosome–positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) progressing after...
Breast Cancer Treatment Options Vary Widely in Cost-Effectiveness
A study published by Smith et al in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment...
Study Finds Link Between Telomere Length and Neighborhood Circumstances
Researchers at Fox Chase Cancer Center have begun to establish a biological basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Program at Fox Chase, led a team...
Avelumab in Refractory Metastatic Urothelial Carcinoma
The programmed cell death ligand 1 (PD-L1)–inhibitor avelumab (Bavencio) has shown activity in patients with refractory metastatic urothelial cancer, according to findings in a phase Ib study reported by Apolo et al in the Journal of Clinical Oncology. This patient cohort is part of the...
Lenalidomide, Bortezomib, and Dexamethasone With or Without HCT in Younger Patients With Multiple Myeloma
A French phase III trial (IFM 2009), reported by Attal et al in The New England Journal of Medicine, has shown that consolidation treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) was associated with poorer progression-free survival vs high-dose chemotherapy and...
AACR 2017: Telomere Length May Predict Cancer Risk, According to Large Epidemiologic Study
The length of the telomeres that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute (UPCI) scientists reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting in...
AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Interim results from the phase Ib/II FB-10 clinical trial of neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1, Kadcyla) were reported in a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, according...
Patient-Reported Outcomes With Immediate Implant-Based or Autologous Breast Reconstruction
As reported in the Journal of Clinical Oncology by Pusic et al, patient-reported outcomes in the Mastectomy Reconstruction Outcomes Consortium Study indicate that autologous tissue breast reconstruction is associated with greater breast satisfaction and greater sexual and psychosocial well-being...
Cardiac Events After Radiotherapy for Locally Advanced Lung Cancer
An analysis of patients from 4 prospective radiotherapy trials for locally advanced non–small cell lung cancer (NSCLC) conducted at 2 centers in Michigan showed that grade ≥ 3 cardiac events occurred in more than 10% of patients. The study was reported by Dess et al in the Journal of...
Thomas E. Starzl, MD, PhD, ‘Father of Modern Transplantation,’ Dies at Age 90
Scientific and clinical pioneers have one thing in common: they move beyond their comfort zone and take calculated risks. One such pioneer, whose calculated risks gave hope to otherwise hopelessly ill people, was Thomas E. Starzl, MD, PhD, who performed the world’s first successful liver...
Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
On March 13, the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) was approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast ...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Practice-Changing Research: Making Palliative Care a Routine Part of Cancer Care in the United States and Abroad
With its recently issued clinical practice guideline update, reviewed in this issue of The ASCO Post, ASCO has spoken: Interdisciplinary palliative care teams improve the outcomes of cancer care; patients live longer and feel better.1 There is no doubt. Multiple well-designed studies show the...
Cardiac Dysfunction in Survivors of Adult Cancers
The success of cancer therapy has led us to an interesting place. Patients with cancer are certainly concerned about collateral damage that may occur with the treatment of their condition; however, impressive improvements in survival with treatment of many cancers are so compelling that these...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
Listeria-Based Immunotherapy Improves Survival in Metastatic Cervical Cancer
Overall survival in recurrent, metastatic cervical cancer was substantially extended with a Listeria-based immunotherapy approach that targets the human papillomavirus (HPV), investigators reported at the Society of Gynecologic Oncology Annual Meeting.1 Of 50 evaluable patients, 19 were alive at...
Expert Point of View: Alessandro Volpe, MD
Formal discussant of this abstract, Alessandro Volpe, MD, of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, commented that nephron-sparing surgery is recommended for clinical stage T1 tumors; however, when compared with ablation, the advantages of...
Evolving Role for Cryoablation in Treating Small Renal Masses
Selected “healthy” patients with clinical T1 renal cell carcinoma may be safely treated with percutaneous cryoablation, according to a single-center study of experience at the Mayo Clinic.1 “In healthier patients, our experience shows that cryoablation achieved good short-term oncologic control...
Elizabeth M. Jaffee, MD, Named AACR President-Elect 2017–2018
Elizabeth M. Jaffee, MD, was elected by the members of the American Association for Cancer Research (AACR) as its President-Elect for 2017–2018. She officially became President-Elect at the AACR Annual Meeting 2017, held in Washington, April 1–5, and will assume the presidency in April 2018 at the ...
Deane L. Wolcott, MD, FAPOS, Receives Holland Distinguished Leadership Award
Deane L. Wolcott, MD, FAPOS, is the 2017 recipient of the Holland Distinguished Leadership Award, which was presented recently at the American Psychosocial Oncology Society (APOS) Annual Conference in Orlando, Florida. Dr. Wolcott is the founding Director of Oncology Supportive Care Services at...
Young Women With Metastatic Breast Cancer: Unique Needs and Concerns
Patients with breast cancer who perceive having enough and the right kinds of social support tend to be less stressed, although a paucity of research exists on the social support needs of young women with metastatic breast cancer, according to Amanda Ginter, PhD. Dr. Ginter, Assistant Professor in ...
Harnessing Implementation Science to Improve Cancer Care Delivery
Implementation science encompasses the study of methods to accelerate integration of evidence into practice and policy to improve health-care outcomes. At the 2017 ASCO Quality Care Symposium, Sandra A. Mitchell, PhD, CRNP, of the Division of Cancer Control and Population Sciences at the National...
FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (Bavencio) on March 23, 2017, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy. Avelumab is a...
AACR 2017: Minority Patients With Colorectal Cancer Report Higher Burden of Poor Quality-of-Life Than Whites
A study presented by Hildebrandt et al at the 2017 Annual Meeting of the American Association of Cancer Research (AACR; Abstract 990) revealed several findings about racial disparities in health-related quality of life among colorectal cancer patients. Hispanics and blacks had a higher burden of...
AACR 2017: Combination Immunotherapies Show Clinical Activity in Metastatic RCC in Pilot Study
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (RCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. The results of...
Use of ‘Triggers’ for Palliative Care Consultation on Solid Tumor Oncology Service
In a study reported in the Journal of Oncology Practice, Adelson et al found that using standardized criteria for palliative care consultation on a solid tumor oncology service resulted in increased hospice referral and reduced rates of hospital readmission and chemotherapy use after discharge....
Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy for Stage I Endometrial Cancer
A multinational equivalence trial has shown no difference in disease-free survival with total laparoscopic hysterectomy vs total abdominal hysterectomy in women with treatment-naive stage I endometrial cancer. The findings were reported by Janda et al in JAMA. Study Details In the trial, 760...
